TScan Therapeutics, Inc.
TCRX
$0.97
$0.1315.33%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 9.14M | 10.33M | 8.42M | 6.96M | 4.42M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.14M | 10.33M | 8.42M | 6.96M | 4.42M |
| Cost of Revenue | 104.67M | 112.55M | 123.47M | 118.04M | 112.28M |
| Gross Profit | -95.53M | -102.23M | -115.04M | -111.08M | -107.86M |
| SG&A Expenses | 31.17M | 31.59M | 33.63M | 33.16M | 31.84M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 135.84M | 144.14M | 157.09M | 151.20M | 144.12M |
| Operating Income | -126.70M | -133.81M | -148.67M | -144.24M | -139.70M |
| Income Before Tax | -124.31M | -129.77M | -142.60M | -136.78M | -131.48M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -124.31 | -129.77 | -142.60 | -136.78 | -131.48 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -124.31M | -129.77M | -142.60M | -136.78M | -131.48M |
| EBIT | -126.70M | -133.81M | -148.67M | -144.24M | -139.70M |
| EBITDA | -123.82M | -130.95M | -145.81M | -141.12M | -136.17M |
| EPS Basic | -1.93 | -2.06 | -2.52 | -2.45 | -2.39 |
| Normalized Basic EPS | -1.20 | -1.28 | -1.56 | -1.52 | -1.48 |
| EPS Diluted | -1.93 | -2.06 | -2.52 | -2.45 | -2.39 |
| Normalized Diluted EPS | -1.20 | -1.28 | -1.56 | -1.52 | -1.48 |
| Average Basic Shares Outstanding | 303.46M | 299.95M | 226.68M | 223.28M | 219.47M |
| Average Diluted Shares Outstanding | 303.46M | 299.95M | 226.68M | 223.28M | 219.47M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |